Use of Angiotensin II for Post Cardiopulmonary Bypass Vasoplegic Syndrome

Adam Evans; Michael T McCurdy; Menachem Weiner; Bledi Zaku; Jonathan H Chow

doi:10.1016/j.athoracsur.2018.11.047

Use of Angiotensin II for Post Cardiopulmonary Bypass Vasoplegic Syndrome

Ann Thorac Surg. 2019 Jul;108(1):e5-e7. doi: 10.1016/j.athoracsur.2018.11.047. Epub 2018 Dec 21.

Authors

Adam Evans¹, Michael T McCurdy², Menachem Weiner³, Bledi Zaku⁴, Jonathan H Chow⁵

Affiliations

¹ Department of Anesthesiology, Morristown Medical Center, Morristown, New Jersey.
² Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
³ Department of Anesthesiology, Icahn School of Medicine at Mount Sinai, New York, New York.
⁴ Department of Surgery, Morristown Medical Center, Morristown, New Jersey.
⁵ Division of Critical Care Medicine, Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland. Electronic address: jchow@som.umaryland.edu.

PMID: 30582924
DOI: 10.1016/j.athoracsur.2018.11.047

Abstract

Angiotensin II is a novel vasopressor recently approved for the treatment of vasodilatory shock. We describe a case in which Angiotensin II was used to treat post-cardiopulmonary bypass vasoplegic syndrome in a patient who was refractory to standard vasopressors and other rescue therapies. Despite requiring high-dose vasopressors, the patient was extubated within 24 hours and has met key quality metrics defined by The Society of Thoracic Surgeons.

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Angiotensin II / therapeutic use*
Cardiopulmonary Bypass / adverse effects*
Humans
Male
Methylene Blue / therapeutic use
Vasoplegia / drug therapy*

Substances

Angiotensin II
Methylene Blue